Replies to post #337117 on NorthWest Biotherapeutics Inc (NWBO)

[trocprofit]

100%.

[JRIII]

Their inability to meet any timeline is keeping the SP down

It's not an "inability". It is 100 percent willful. They have been playing games with shareholders for many years, and what they are doing now is continuing their efforts to secretly manipulate the data to meet a desired outcome.

The way I see it, there are two equally likely possibilities from here:

Scenario 1) They release the data on Monday, Dec. 14, ahead of the options deadline. It will be a puffed up press release that talks about the great contribution this trial will make to the field of cancer vaccine research. Of course, what it will be referring to is future cancer vaccine research, because the data will show a failed trial due to invalid comparisons. Knowing these people as I do, I predict they will try to present a failed trial as actually being a successful trial, because the invalid comparisons may reflect minimal efficacy in one or two endpoints. They will tout this as actual success, and decry the injustice of having their grossly manipulated trial ruled invalid.

Stock price will plummet.

Scenario 2) They announce the warrants have been extended again - until March or April at least - and at the same time announce another cash raise that further dilutes common shareholders so they can keep paying themselves. Wash, rinse, repeat. In this scenario we carry on as we always have, and begin talking about making a really, really tough list of questions for the ASM, and then begin hyping the super expensive and professional looking background the company has created for its 2021 ASCO Zoom presentation. Everything proceeds per usual until we eventually get back around to Scenario 1.

Stock price drops under a dollar, and begins a slow decline back to $.17

It will be one of these two scenarios. Count on it.